Abionyx Pharma (FRA:609) ROCE %: -74.96% (As of Dec. 2025)


FRA:609 Abionyx Pharma FRA:609
15 GF Score
Price €2.17
GF Value €0.80
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma ROCE %?

Abionyx Pharma FRA:609 +1.17% 15 ROCE % is -74.96% as of Dec. 2025. GuruFocus rates FRA:609 with a GF Score™ of 15/100 and a GF Value™ of €0.80 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abionyx Pharma's annualized ROCE % for the quarter that ended in Dec. 2025 was -74.96%.

Abionyx Pharma  (FRA:609) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abionyx Pharma ROCE % Related Terms

Abionyx Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Abionyx Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma ROCE % Chart

Abionyx Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.40 -32.11 -32.34 -41.88 -61.34

Abionyx Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.55 -35.88 -41.38 -47.22 -74.96
FRA:609
15GF Score
Abionyx Pharma FRA:609
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma ROCE % Calculation

Abionyx Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-5.456/( ( (13.541 - 3.705) + (13.115 - 5.163) )/ 2 )
=-5.456/( (9.836+7.952)/ 2 )
=-5.456/8.894
=-61.34 %

Abionyx Pharma's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-6.422/( ( (13.065 - 3.882) + (13.115 - 5.163) )/ 2 )
=-6.422/( ( 9.183 + 7.952 )/ 2 )
=-6.422/8.5675
=-74.96 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -74.96% mean?
Abionyx Pharma (FRA:609) has a ROCE % of -74.96% as of Dec. 2025.
Is Abionyx Pharma's ROCE % too high?
Abionyx Pharma's current ROCE % is -74.96%. Overall, Abionyx Pharma has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's ROCE % compare to VRTX and REGN?
Abionyx Pharma's ROCE % of -74.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Abionyx Pharma's current ROCE % is -74.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.80, compared to a current price of €2.17 — trading 171.3% above its estimated fair value. The current ROCE % is -74.96%. Abionyx Pharma's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current ROCE % is -74.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €2.17 is trading 171.3% above its estimated GF Value™ of €0.80. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

  • ROCE %: -74.96%
  • GF Value™: €0.80 vs. price of €2.17 (171.3% above fair value)
  • GF Score™: 15/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
15GF Score

Get the complete analysis for FRA:609

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.17
Price
€0.80
GF Value